Background: Elevated Epstein–Barr virus (EBV) antibody titers are risk factors for multiple sclerosis (MS), but the strength and consistency of this association are not well characterized.
Objectives: The objectives of this study were to determine whether this association is confounded by vitamin D or modified by gender or race, and the usefulness of EBV nuclear antigen (EBNA) antibodies as a marker for MS.
Methods: We conducted a prospective study among US military personnel. Antibody titers against EBV antigens were measured in serum samples from 222 individuals who developed MS and 444 age, sex, and race/ethnicity matched controls. Conditional logistic regression was used to estimate relative risks.
Results: MS risk increased with increasing titers of anti-EBNA complex (p < 10−9) and anti-EBNA-1 (p = 5.8 × 10−9) titers. MS risk was 36-fold higher among individuals with anti-EBNA complex IgG titers ≥320 than among those with titers <20 (95% confidence interval [CI] 9.6–136), and 8-fold higher among those with anti-EBNA-1 ≥320 than among those with anti-EBNA-1 <20 (95% CI 2.6–23). These associations were consistent across gender and race/ethnicity groups and independent from 25-hydroxyvitamin D levels. Areas under the receiver operating characteristic (ROC) curves were 0.67 for EBNA complex and 0.65 for EBNA-1.
Conclusions: Serum titers of pre-onset anti-EBNA antibodies are strong, robust markers of MS risk and could be useful in an MS risk score.
AscherioAMungerKL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol2007; 61: 288–299.
2.
AscherioAMungerKL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol2007; 61: 504–513.
3.
DymentDAEbersGCSadovnickAD. Genetics of multiple sclerosis. Lancet Neurol2004; 3: 104–110.
4.
LevinLIMungerKLO’ReillyEJFalkKIAscherioA. Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol2010; 67: 824–830.
5.
AscherioAMungerKLLennetteET. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA2001; 286: 3083–3088.
6.
SundstromPJutoPWadellG. An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology2004; 62: 2277–2282.
7.
LevinLIMungerKLRubertoneMV. Temporal relationship between elevation of Epstein–Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA2005; 293: 2496–2500.
8.
DelorenzeGNMungerKLLennetteETOrentreichNVogelmanJHAscherioA. Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol2006; 63: 839–844.
9.
MungerKLLevinLIHollisBWHowardNSAscherioA. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA2006; 296: 2832–2838.
10.
RubertoneMVBrundageJF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health2002; 92: 1900–1904.
11.
HollisBWKamerudJQSelvaagSRLorenzJDNapoliJL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem1993; 39: 529–533.
12.
SchmidtHWilliamsonDAshley-KochA. HLA-DR15 Haplotype and Multiple Sclerosis: A HuGE Review. Am J Epidemiol2007; 165: 1097–1109.
13.
De JagerPLSimonKCMungerKLRiouxJDHaflerDAAscherioA. Integrating risk factors: HLA-DRB1*1501 and Epstein–Barr virus in multiple sclerosis. Neurology2008; 70: 1113–1118.
14.
De JagerPLJiaXWangJ. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet2009; 41: 776–782.
15.
The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet2009; 41: 824–830.
16.
SimonKCvan der MeiIAMungerKL. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology2010; 74: 1365–1371.
17.
ProvvediniDMTsoukasCDDeftosLJManolagasSC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science1983; 221: 1181–1183.
18.
ProvvediniDMTsoukasCDDeftosLJManolagasSC. 1 alpha,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol1986; 136: 2734–2740.
19.
AscherioAMunchM. Epstein–Barr virus and multiple sclerosis. Epidemiology2000; 11: 220–224.
20.
AscherioAMungerKL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol2007; 61: 288–299.
21.
AlotaibiSKennedyJTellierRStephensDBanwellB. Epstein–Barr virus in pediatric multiple sclerosis. JAMA2004; 291: 1875–1879.
22.
ThackerELMirzaeiFAscherioA. Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis. Ann Neurol2006; 59: 499–503.
23.
HandelAEWilliamsonAJDisantoGHandunnetthiLGiovannoniGRamagopalanSV. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One2010; 5–5.
24.
SerafiniBRosicarelliBFranciottaD. Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J Exp Med2007; 204: 2899–2912.
25.
WillisSNStadelmannCRodigSJ. Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain2009; 132: 3318–3328.
26.
PeferoenLALamersFLodderLN. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain2010; 133: e137–e137.
27.
SargsyanSAShearerAJRitchieAM. Absence of Epstein–Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology2010; 74: 1127–1135.
28.
AscherioABar-OrA. EBV and brain matter(s)?. Neurology2010; 74: 1092–1095.
29.
LangHLJacobsenHIkemizuS. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol2002; 3: 940–943.
30.
HollsbergPHansenHJHaahrS. Altered CD8+T cell responses to selected Epstein–Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol2003; 132: 137–143.
31.
HolmoyTVartdalF. Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein–Barr virus-transformed B cells. J Neurovirol2004; 10: 52–56.
32.
AscherioAMungerKL. Epstein–Barr Virus Infection and Multiple Sclerosis: A Review. J Neuroimmune Pharmacol2010; 5: 271–277.
33.
CepokSZhouDSrivastavaR. Identification of Epstein–Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest2005; 115: 1352–1360.
34.
LunemannJDEdwardsNMuraroPA. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain2006; 129: 1493–1506.
35.
De JagerPLChibnikLBCuiJ. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol2009; 8: 1111–1119.
